Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Rapport Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational sma... Rapport Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts. Mostrar más
BOSTON and SAN DIEGO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Rapport Therapeutics, Inc. (Nasdaq: RAPP), please note the references to the...
In the PET trial, RAP-219 achieved and exceeded target receptor occupancy, increasing support for the dosing regimen utilized in the ongoing Phase 2a trial in focal epilepsy; restricted...
A 30% reduction in long episodes was shown to be associated with a 50% or greater reduction in clinical seizures in a post-hoc analysis, validating the biomarker for proof-of-concept studies...
BOSTON and SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small...
| Período † | Variación(Ptos) | Variación % | Apertura | Precio Máximo | Precio Mínimo | Avg. Vol. diario | Precio Promedio Ponderado | |
|---|---|---|---|---|---|---|---|---|
| 1 | 3.22 | 22.5174825175 | 14.3 | 18.2675 | 14.0453 | 115338 | 16.6697776 | CS |
| 4 | 0.1 | 0.574052812859 | 17.42 | 18.2675 | 12.0948 | 106038 | 14.78321797 | CS |
| 12 | -6.88 | -28.1967213115 | 24.4 | 24.7 | 12.0948 | 114866 | 18.55078508 | CS |
| 26 | -3.088 | -14.9844720497 | 20.608 | 29.74 | 12.0948 | 130254 | 20.42616449 | CS |
| 52 | -0.48 | -2.66666666667 | 18 | 29.74 | 12.0948 | 147800 | 21.32407124 | CS |
| 156 | -0.48 | -2.66666666667 | 18 | 29.74 | 12.0948 | 147800 | 21.32407124 | CS |
| 260 | -0.48 | -2.66666666667 | 18 | 29.74 | 12.0948 | 147800 | 21.32407124 | CS |
NASDAQ2020
1 minuto hace
weekend farmer
2 minutos hace
Samuel J
2 minutos hace
Jackxkr
2 minutos hace
Good time Charlie
2 minutos hace
INV4
2 minutos hace
Carl Hanratty
2 minutos hace
getmoreshares
2 minutos hace
abazaba375
2 minutos hace
falconer66a
3 minutos hace
Gregg4
3 minutos hace
chemist72
3 minutos hace
mascale
3 minutos hace
Stockster
3 minutos hace
Jackxkr
3 minutos hace
jour_trader
4 minutos hace
mrnutsandbolts
4 minutos hace
Stevekkk1
4 minutos hace
jog49
4 minutos hace
fink
4 minutos hace
Risk
4 minutos hace
elks
4 minutos hace
littlejohn
4 minutos hace
Parece que no se ha autenticado. Haga click al botón de abajo para iniciar la sesión y ver los símbolos recientemente consultados.
Soporte: (55) 4170 8128 | soporte@advfn.mx
Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones
Hot Features
Premium
